Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lysosome is a specialized membrane-bound organelle that serves as the cell's primary digestive and recycling center, maintaining cellular homeostasis through the degradation of macromolecules via endocytic and autophagic pathways [3, 4]. Its degradative capacity is strictly dependent on a highly acidic internal environment (pH 4.5–5.0), which is primarily established and maintained by the vacuolar-type H+-ATPase (V-ATPase) proton pump [15, 18]. Within this acidic lumen, a suite of over 60 lysosomal proteins, including acid hydrolases like cathepsins and glucocerebrosidase, catalyze the breakdown of proteins, lipids, and complex sugars [6, 11]. Dysregulation of lysosomal pH or genetic defects in lysosomal proteins are central to the pathogenesis of lysosomal storage diseases (LSDs) and are increasingly implicated in common neurodegenerative conditions such as Parkinson’s and Alzheimer’s diseases [2, 7]. Therapeutically, the lysosome is targeted through several distinct strategies depending on the disease context, such as enzyme replacement therapies (ERT) and pharmacological chaperones used to restore the activity of specific defective lysosomal proteins [13]. In neurodegeneration, emerging small molecules and nanoparticles aim to restore lysosomal acidification to enhance the clearance of toxic protein aggregates [5, 10]. Conversely, in oncology, lysosomotropic agents like chloroquine are used to inhibit lysosomal function, thereby blocking autophagy and sensitizing cancer cells to chemotherapy [9, 12]. Additionally, the acidic nature of the lysosome leads to the sequestration of many basic lipophilic drugs, a phenomenon known as lysosomal trapping, which can significantly influence drug pharmacokinetics and safety [14].
Modulation of intralysosomal pH via V-ATPase inhibition or re-acidification, enzyme replacement, and pharmacological chaperoning of lysosomal hydrolases.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysosomal proteins and acidification machinery.